九典制药(300705) - 300705九典制药投资者关系管理信息20250929

Group 1: Strategic Focus and Innovation - The company is fully transforming to focus on innovative drug research and development, with a core direction in chemical and traditional Chinese medicine innovation [2] - Key therapeutic areas include pain management, focusing on peptide and small molecule drugs, and oncology, with a focus on PDC drug development [2] - The company employs a dual approach of independent research and project acquisition to build core technological barriers and accelerate innovation results [3] Group 2: Product Launch and Market Expectations - The ketoprofen gel patch was approved for market launch in 2023 and has entered the national medical insurance directory, being the first generic product in the market [4] - The company has optimistic market expectations for the ketoprofen gel patch and has developed new sales strategies focusing on external markets [4] Group 3: Research and Development Investment - The estimated R&D expenditure for 2025 is projected to be between 250 million and 300 million yuan [5] Group 4: Employee Incentives and Governance - The company is implementing a share repurchase plan to support future equity incentive plans, aiming to enhance governance and align interests among stakeholders [6] Group 5: New Product Highlights - The newly introduced innovative drug JIJ02 gel has broad-spectrum antibacterial properties, low cost, and is expected to have significant market competitiveness [7][8] - JIJ02 gel is anticipated to complete Phase I clinical trials by mid-next year and will initiate Phase II trials thereafter [8] Group 6: Pricing and Procurement - The company is currently in the bidding phase for the 11th batch of national drug procurement, with submission of application materials and public pricing information due by October 21 [8]